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ABSTRACT 
The dystrophin gene has been localised to Xp 21.1. Mutations of this 
gene can lead to the clinical manifestations of Duchenne and Becker 
muscular dystrophies (DMD/BMD). In the majority of DMD and BMD 
patients the disease-causing mutation is a deletion detectable by 
southern analysis or multiplex PCB, however in 30% of patients no 
deletion is observed using these conventional tests. Using PCR 
amplification of eDNA it was possible to detect a deletion in the 
product of the dystrophin gene of one such individual affected with 
BMD. It was then necessary to characterise the mutation in order to 
determine whether this was the disease-causing mutation. The 
mutation was found to be a point mutation by genomic sequencing at 
the donor splice site consensus sequence of intron 19. This resulted in 
alternate splicing of exon 19, two mANA transcripts being produced 
one with exon 19 and the other without. This was determined sufficient 
to cause BMD in the family. It was then necessary to provide an easy 
and efficient diagnostic test in order to determine the carrier status of 
females and also to provide those females determined to be carriers 
with an accurate prenatal diagnostic test. A new technique, single 
strand conformation polymorphism, performed on genomic DNA 
provided evidence of conformational difference between the affected 
allele and the normal allele. Allele specific primers were also 
designed and optimised. These primers, 19FA and 19FC, only varied 
at one base, one being the "normal" allele primer and the other the 
"affected" allele primer. The amplified product using primers for the 
normal and the affected allele were then run on agarose gels and 
iii 
stained with ethidium bromide providing a quick and easy method of 
determining the carrier, affected or normal status of all family 
members. 
The localisation and characterisation of this splice site mutation 
involved many molecular techniques including, RNA extraction, eDNA 
synthesis, nested amplification, sequencing, single strand 
conformation polymorphism and the amplification refractory mutation 
system. All of these techniques can be used to isolate and 
characterise point or minor mutations in the 30% of Western 
Australian dystrophic families, who currently lack an accurate 
diagnostic test lor their dystrophic condition. 
iv 
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Chapter 1: INTRODUCTION 
1.1 General introduction 
Mutations in the dystrophin gene can result not only in Duchenne 
muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) but 
also familial X-linked myalgia and cramps, which is a non progressive 
myopathy associated with a deletion in the dystrophin gene (Gaspe et 
al, 1989; Hodgson et al, 1989; Prior et al, 1990). DMD and BIViJ are 
progressively degenerative diseases which show a great deal of 
variation in both genetic and protein structure. These variations along 
1 with other as yet unknown factors, determine the speed at which the 
disease progresses (Koenig et al, 1989). 
1.2 Duchenne and Becker muscular dystrophy 
Duchenne muscular dystrophy and Becker muscular dystrophy are 
allelic disorders caused by mutations of the dystrophin gene (Koenig 
et al, 1989). DMD, the more severe of these dystrophinopathies, 
occurs in approximately 1 in 3500 male births (Hodgson et al, 1989). 
BMD, the milder allelic disorder, has a. much lower incidence of 
approximately 1 in 30 000 males (Koenig et al, 1989; Prior et al, 1990). 
The ipcidence of BMD may prove to be much hig_her now that 
• 
complementary deoxyribonucleic acid (eDNA) probes have been used 
c 
to reclassify many limb-girdle muscular dystrophy and spinal muscular 
atrophy patients as having BMD (Norman et al; 1989; Patel et al, 
1989). 
The phenotypes of affected boys have been sub-classified into 3 
groups based on the age at which ambulation was lost. Group 1 boys 
have DMD and are wheelchair bound by age 13. Group 2 boys form 
1 
an intermediate group and are wheelchair bound between the ages of 
13 and 16. Group 3 boys have BMD and become wheelchair bound 
after the age of 16 or may never lose ambulation (Hodgson et al, 1989; 
Prior et al, 1990). 
Duchenne and Becker muscular dystrophies are X-linked recessive 
disorders. X-linked recessive disorders generally only affect males and 
are passed througil carrier women. Carrier women are usually 
unaffected since the mutated gene is compensated for by the normal 
gene on their other X chromosome. All daughters of affected men are 
carriers, and the disease is never transmitted from father to son (see 
, Figure 1.1) (Gelehrter & Collins, 1990, p. 41 ). 
1 .3 Dystrophin gene 
The discovery of the dystrophin gene by Kunkel and his co-workers, 
(1986) has resulted in a substantial increase in research into both the 
structure and function of the dystrophin gene (Hoffman et al, 1987; 
Beggs et al, 1990). The dystrophin gene was first sub-localised on the 
X chromosome by cytogenetic analysis of several DMD patients with 
deletions and translocations of the X chromosome (Francke et al, 
1985;. Boyd et al, 1986; Beggs et al, 1990). These cytogenetic 
analy§es demonstrated abnormalities in the middle of t~e short arm of 
• 
. the X chromosome (Xp 21 ). The localisation was then confirmed by 
linkage analysis, using polymorphic markers on the short arm of the X 
chromosome. These markers were inherited with the disease causing 
mutation more than 50% of the time, as would be expected with linked 
markers (Laing, 1993). Once the gene that resulted in DMD was 
isolated it was then possible to use genomic deoxyribonucleic acid 
2 
Figure 1.1 
X-linked recessive inheritance as in Duchenne/Becker 
muscular dystrophies. This pedigree shows how the 
probability of inheriting an X-linked gene is 0.5. Males 
because of their XY hemizygous condition, have a 50% 
ghance of being affected by an X-linked disorder. The XX 
• 
genotype of females provides them with protection from 
phenotypic manifestations of X-linked recessive disorders, 
however in affected families they have a 50% chance of 
·inheriting an X·linked disease gene and therefore have a 
50% chance of being carriers of such X-linked disease genes. 
,. 
. .. 
3 
Figure 1.2 
Four domains of dystrophin are represented on this tentative 
~chematic diagram. The conformation of the actin-binding, 
cysteine-rich and C-terminal domains is purely speculative 
and are represented as broad loops simply to illustrate that 
they may adopt a more globulal structure, than the rod section. 
The rod section is formed by 25 triple helical segments 
(Koenig et al, 1988). 
• 
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Carpenter et al (1990) and Watkins et al (1988), both localised 
dystrophin at or close to the plasma membrane of human skeletal 
muscle. The use of both light and electron microscopy has shown 
dystrophin to be located in the sarcolemma of the muscle and 
immunostaining showed particular prominence of dystrophin at the 
myotendinous junction (Campbell et al, 1989; .Knudson et al, 1990). 
Some of the proposed functions of dystrophln are:-
1) A role in excitation and contraction coupling. The early localisation 
studies showed dystrophin to be enriched on the T-tubules at the 
triadic junction of skeletal muscle (Knudson et al, 1990; Harris et al, 
1992). 
2) Involvement in the regulation of ca++ movement. In this case it is 
said the dystrophin is bound to stretch-inactivRted channels. In a 
dystrophin deficient state, these channels remain open allowing a 
continual influx of ca++. It must be noted that it is not known by what 
mechanism dystrophin affects the ca++ channels (Turner et al, 1988; 
Harris et al, 1992). 
3) . Maintenance of flexibility and stability ot'the plasma membrane. It is 
thought the C-terminus is bound tightly to the plasma membrane 
? -glycoproteins, while the amino terminus is attached to the 
cytoskeleton. This provides the plasma membrane with protection from 
stretching. (Watkins et al, 1988; Harris et al, 1992) .. : 
1-5 Reading frame theory 
Irrespective of the role of dystrophin it has been established that the 
size of the deletion does not provide information as to the severity of 
the disease (Hodgson et al, 1989). It was proposed by Koenig et al 
8 
(1989), 1hat mutations which maintained the reading frame of mRNA 
resulted in the milder BMD, while DMD occurs when the reading frame 
is disrupted, due to the insertion of a stop codon. This stop codon in 
DMD patients resulted in a severely truncated protein (Hodgson et al, 
1989; Koenig et al, 1989). It was subsequently shown by Koenig et al 
(1989), that this was not always the case. In 60 out of 70 BMD patients, 
deletions in the Dystrophin gene had maintained the reading frame 
and in 178 out of 188 DMD patients, deletions had disrupted the 
reading frame. It was evident from these results that approximately 
92% of DMD and BMD patients fitted the reading frame model. 
Western blot analysis also showed that DMD muscle, when tested with 
' specific carboxy terminus antiserum, gave negative results. BMD when 
tested with the same carboxy antiserum gave a positive result, but with 
reduced protein size and expression (Tanaka et al, 1990; Harris et al, 
. 1992). This was an indication of a mutation that has maintained the 
reading frame. Hodgson et al (1989), showed that the same deletion in 
different patients could result in different phenotypic manifestations. 
This suggested that other factors might influence the phenotypic 
response to a mutation. Chelly et al (1990), suggested that alternate 
splicing might explain the exceptions to the'reading frame theory. 
. -· . 
1.6 ,. Splicing 
' 
in higher eukaryotes some pre-mRNAs undergo alternate splicing, 
which increases the number of protein products ~f a single gene and 
provides additional mechanisms for regulating gene expression 
(Green, 1986). Alternate splicing can result in the skipping of specific 
exons, therefore generating multiplE! mRNAs from a single pre-mRNA 
(Green, 1986). 
9 
The process of transcription involves the synthesis of a single-stranded 
mRNA molecule from the double-stranded DNA template in the cell 
nucleus. Transcription of DNA is selective, with specific regulatory 
sequences indicating the beginning and the end of the segments of 
DNA to be transcribed. Transcription of a gene results in many 
identical single-stranded transcripts containing_ both introns and exons. 
This pre-mRNA then needs to have the intronic (non-protein coding 
region) mRNA spliced aut before it can became mature mRNA and 
subsequently leave the nucleus (Green, 1986; Padgett et al, 1986). 
The process at splicing intronic RNA out of pre-mRNA to make mature 
mRNA is not well understood (Ruby & Abelson, 1991 ). Small nuclear 
RNA's (snRNA) are involved in this splicing. In particular a subset of 
these snRNA's known as U1, U2, U4, US, U6, U7, UB, US, U1 0, 
. have been shown to form complexes with small nuclear 
ribonucleoproteins (snRNP's). The snRNA U1 is the first to bind to the 
pre-mRNA and is complementary to the consensus sequence at the S' 
splice site. Consensus sequences play an important functional role in 
gene expression and although the sequence may not be identical from 
gene. to gene, they do tend to share· certain features. US is 
. "~· 
complementary to the 3' splice site. These two snRNA's along with the 
. -
other snRNA's and the associated snRNP's form a complex known as 
a spliceosome, which causes a looping of the intronic mRNA and 
subsequent splicing out of the intron, to form the mature mRNA (Ruby, 
1991 ). It does this by acting as a temporary clamp to hold the two 
consecutive exons together so that enzymatic splicing occurs at the 
correct point. The process of spliceosome formation requires ATP 
(Green, 1986; Padgett et al, 1986; Gunzel et al, 1992): 
10 
The 5' and 3' ends of introns contain only two universally conserved 
dinucleotides, the first and last two nucleotides of the intron. The first 
two nucleotides, known as the donor splice site are located at the 5' 
end of the intron and consists of a Guanine and a Uracil. The last two 
nucleotides, known as the acceptor splice site are located at the 3' end 
of the intron and consist of an Adenine and a Guanine (see Figure 1.3) 
(Green, 1986; Padgett et al, 1986). 
At the exon-intron boundaries, there is also a conserved sequence 
{)t 
which provides binding sites for snRNA's. At the Donor site 5' end 
there is an eight nucleotide semi conserved consensus sequence, two 
1 residues 5' and six residues 3' from the splice point. The actual 
nucleotide frequencies upon which the consensus is based are A 
64%, G 73%, I G 100%, U 100%, A 62%, A 68%, G 84%, U 63%. 
Beyond this region the sequence is again random (Green, 1986). At 
the Acceptor site 3' end of this intron, the consensus sequence is of 
variable length (greater than ten nucleotides), 1 residue 3' and a 
variable number of residues 5' from the splice point, which includes a 
pyrimidine rich region and the universally conserved "AG" dinucleotide 
(see Figure 1.3) (Green, 1986; Padgett et ~1. 1986). 
Thi>'function of introns is not well understood, although they may 
" provide extra genetic flexibility. This versatility is confelied by alternate 
patterns of mRNA splicing which can generate different proteins from 
the same mRNA transcript although there is no l;lpparent mutation at 
the donor or acceptor splice sites. Alternative splicing_ of mRNA can be 
related to tissue-specific splicing ie. different mature mRNA products 
are spliced in different tissue samples {lnazu et al, 1992). Alternate 
11 
• 
Figure 1.3 
' 
,Splicing of pre·mRNA results in mRNA, which then leaves the 
nucleus. Donor and Acceptor splice sites indicate the region of 
HNA to be spliced out and are universally conserved. The 
donor consensus sequence is semi-conserved and necessary 
' 
·for accurate splicing to occur. 
·. . ... 
• 
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splicing can also occur at different times during development, resulting 
again in changes in the mature mRNA transcript (Green, 1986). It is 
also possible to have non-regulated splicing. For example this occurs 
in the adenovirus allowing the virus to produce multiple protein 
products from a single transcription unit (Green, 1986). 
1. 7 Mutations in the dystrophin gene 
and disease detection 
Mutations at the donor and acceptor splice sites of a gene have been 
shown to produce various effects in the formation of mature mRNA. 
These include exon skipping, insertion of intronic sequence in mRNA 
and partial insertions and deletions of both exons and introns into 
mRNAwhich may or may-not affect the reading frame (Rees et al,1985; 
Cladaras et al, 1987; Mounir et al, 1990; Takahashi et al, 1990; 
Carstens et al, 1991 ). 
In 30% of DMD families and 14% of BMD families there is no easily 
detectable mutation (Laing, 1993). These DMD and BMD patients 
therefore have point or minor mutations of the dystrophin gene, which 
conventional southern analysis or multiple~ polymerase chain reaction 
(PC~) are unable to detect. These ,families must rely on linkage 
analysis for prenatal diagnosis. The accuracy of diagnpsis based on 
• 
Jinkage analysis varies, depending on the distance of the polymorphic 
.-
marker from the disease-causing mutation. Linkage analysis is also 
limited by the number of affected people in a family. For example, if 
only one affected person is seen in the family it is not possible to 
establish linkage between markers and the disease gene and so 
linkage analysis becomes useless in these circumstances. The large 
size of the dystrophin gene 2.5 Mbp and other undefined factors result 
14 
in 11% to 12% recombination across the dystrophin gene (Abbs et al, 
1990). Prenatal diagnosis of DMD/BMD families by linkage analysis 
could result in errors unless tightly-linked highly polymorphic flanking 
markers are used (Laing, 1993). PCR techniques have been used to 
analyse microsatellites (polymorphic markers) at either end of the 
dystrophin gene, to determine linkage. This method of linkage analysis 
is both extremely informative and fast (Webber et al, 1990). The 
problem with linkage analysis is most family pedigrees are not large 
enough to show linkage of the disease with a polymorphic marker. If 
the mutation is de-novo, which is estimated to be the case in 33% of 
DMD/BMD patients, then linkage analysis is of no value (Laing, 1993). 
The best method of offering these families accurate prenatal diagnostic 
testing, would be to Identify the actual point or minor mutation in these 
families that results in DMD/BMD. It is then possible to devise an 
· accurate prenatal diagnostic test based on the disease causing 
mutation. 
1.8 Project outline 
In 70% of DMD and BMD patients the conventional restriction fragment 
length analysis of the dystrophin gene .by southern blots, show notable 
-" 
defeiions, duplications or translocatlons. This provides accurate 
prenatal diagnostic tests for these families. In the othef 30% of DMD 
and BMD patients there is no known deletion or 1ranslocation, 
therefore for these families linkage analysis is· the only means of 
providing a prenatal diagnostic test and this may not always be 
informative. This 30% of patients with DMD and BMD must therefore 
have a small mutation, even a point mutation which is not able to be 
detected by southern analysis (Richards et al, 1991; Laing et al, 1992). 
15 
The project involves looking for small or point mutations, in one 
Western Australian family which does not have a notable deletion 
and/or translocation. If a point or small mutation is identified this will 
provide the basis for an accurate prenatal. diagnostic test for this family. 
It will also enable carrier females to be ide"ntified. To do this I will 
perform a dystrophin gene nested amplification ·of complementary 
DNA (eDNA) from seven affected individuals belonging to seven 
different families. This may gi'Je an indication· of which family is best to 
investigate further, with a view to developing a diagnostic test for their 
, form of muscular dystrophy. In doing the project I will become familiar 
with a large number of molecular techniques, polymerase chain 
reaction (PCR), single strand conformation polymorphism (SSCP), 
amplification refractory mutation system (ARMS) and genomic 
sequencing. 
1. 9 Techniques used to identify mutations 
Roberts et al (1991) and (1992) have described a method for finding 
point mutations in the dystrophin gene. Their method of detecting point 
mu)ations will be used in this project ,with some slight modifications. 
Messenger RNA will be extracted from muscle inste~d of peripheral 
blood lymphocytes. Reverse transcription of mRNA to produce eDNA 
,. 
and nested PCR of the dystrophin gene will be carried out using the 
nested primers specified by Roberts et al (1991 ). 
If no mutation is evident after nested PCR, then SSCP analysis will be 
attempted. Richards and Friend (1991 ), showed SSCP analysis of 
. 
DNA could be used to determine carrier status of dystrophic women. 
Orita et al (1989a), noted that SSCP analysis could be used to detect 
16 
single base changes in sequences under 200 base pairs (bp). SSCP 
is used to analyse the eDNA after it has been amplified [PCR], because 
single strand DNA migrates according to the nucleotide sequence 
which in turn determines the conformation of the DNA and 
subsequently the speed of migration. Therefore a single base change 
in single-stranded DNA may cause a conformation change, which will 
lead to a change in migration speed during electrophoresis. A single 
.. 
base change in double-stranded DNA would not cause a change in 
migration with normal electrophoresis (Orita et al, 1989b; Baldwin et al, 
1992). 
, Once nested PCR or SSCP has determined an area of the dystrophin 
gene to be polymorphic, it is necessary to sequence the genomic DNA 
for that area and determine whether or not there is a sequence 
change from the published eDNA sequence and whether that 
particular change could result in the clinical manifestation of DMD or 
BMD in the individual (Rao & Sanders, 1992). 
The final phase of the project will involve providing the families with 
an accurate prenatal diagnostic test. This could be either using SSCP 
to .characterise the effect of the mutation o~ all the family members, or 
.. ~ 
ano'tlier diagnostic test, known as amplification refractory mutation 
,. 
• system (ARMS). The ARMS method uses primers specific for the 
mutation, to amplify the mutant allele or the normal allele (Wenham et 
al, 1991). 
17 
CHAPTER 2: RNA EXTRACTION AND eDNA SYNTHESIS 
2.1 Introduction 
During ribonucleic acid (RNA) extraction from tissue there are many 
opportunities for contamination with RNAases. RNAases are enzymes 
which can degrade the RNA in the tissue and during the extraction 
procedure (Sambrook et al, 1989). The history of the frozen tissue 
used in this project and its handling at the time before freezing was not 
known and may have resulted in contamination with RNAases. It was 
therefore important to minimise the introduction of RNAases in the 
, extraction procedure, to limit degradation of the RNA still present in the 
tissue. This was done using sterile technique and RNA dedicated 
equipment and solutions. All further analysis carried out on this RNA, 
was done using the polymerase chain reaction (PCR) technique. PCR 
requires only small amounts of mRNA to be converted into eDNA for 
subsequent amplification to occur successfully. As the products being 
amplified were approximately 1250 bp long, it was necessary that 
RNAase activity/presence was minimised so as to allow the production 
of this relatively large eDNA transcript. 
The 'RNA extracted from the muscle' biopsies does not have any 
r ~ 
intronic sequence and is used as a template in thEi'.production of 
eDNA. Converting the mANA to eDNA, by using the enzyme reverse 
transcriptase, reduces the sequence information,: making it easier to 
find minor mutations. Genomic DNA coding for the dystrophin protein 
consists of 2500 kb whereas the eDNA which codes for dystrophin is 
only 11 kb long or 14 kb if promoters and 3' untranslated regions are 
included (Koenig et al, 1987) . 
. 18 
The conversion of RNA to DNA occurs within a group of viruses, known 
as retroviruses. These viruses have a genome composed of single· 
stranded RNA. Upon entering a cell the retrovirus Is uncoated and the 
RNA is copied into DNA by a unique viral enzyme called reverse 
transcriptase (Gelehrter and Collins, t990, p.238). This retroviral 
enzyme can also be used to convert mANA extracted from cells to 
eDNA, resulting in a DNA transcript with no intronic sequence. This 
process of converting single·stranded RNA to double-stranded DNA is 
known as reverse transcription (Watson et al, 1987, p.90). 
Reverse transcription of mANA extracted using RNAzol (Biotecx lab) or 
, the GuHCI (guanidine hydrochloride) methods, was carried out using 
avian myeloblastosis virus reverse transcriptase (AMV-RTase), 
supplied by Promega Corporation. This enzyme synthesises DNA in 
the 5' to 3' direction from a single stranded RNA template, using a 
short primer to initiate synthesis. AMV-RTase works efficiently at 42°C, 
which allows RNA's rich in secondary structures to be copied more 
efficiently than the murine enzyme which works at 37°C (Sambrook, 
1989). The problem associated with both these reverse transcriptase 
enzymes is the lack of 3' - 5' exonuclease. activity, which provides an 
editi~g function and therefore the presence of high concentrations of 
dNTP:s and Mg++ may lead to mis-incorporation (Sambrook et al, 
• 
1989). AMV-RTase enzyme and associated 5x buffer were supplied by 
' 
Pro mega Corporation. The 5x buffer supplied has the concentration of 
dNTP's and Mg++ optimised and therefore reduces any chance of mls-
incorporation during eDNA synthesis. 
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2.2 Materials and Methods 
Two methods of RNA extraction were used. RNAzol (Biotecx lab) and a 
modified GuHCI method (Chirgwin et al, 1979). 
Note: all reagents used in this honours project were of analytical 
grade. 
2.2.1 RNAzol (Biotecx lab) 
This is a new method of RNA extraction and the ingredients which 
make up RNAzol remain a closely guarded secret of Biotecx Inc. The 
benefit of this method of RNA extraction is that it requires minimal steps 
and time in order to get good RNA yields. The RNA extraction consists 
of four steps :· 
1. Homogenisation (tissue) 
2. RNA extraction 
3. RNA precipitation 
4. RNA wash 
The RNAzol method of extracting RNA can be completed within 2 
hours. The methodology used for the ext('iCtion of RNA in this case 
was hi compliance with the RNAzol preduct information pamphlet and 
is as follows:- ... 
A muscle sample (5·1 Omg) was placed in a 1.5ml reaCtion tube and 
200ul of RNAzol was added. The muscle was then homogenised using 
a sterile, disposable, plastic homogeniser. 20ul of chloroform was theD 
added to the homogenate and the sample shaken vigorously for fifteen 
seconds. The sample was then left on ice for five minutes and then 
spun down at 11500g (4°C) for 15 minutes. At this stage two phases 
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formed, an upper colourless phase and a iower blue phenol-
chloroform phase. RNA remains in the upper colourless phase. The 
upper phase was then transferred to a fresh 1.5ml reaction tube, with 
an equal volume of isopropanol and then stored for 15 minutes at 4°C. 
The sample was then spun in a centrifuge at 11500g (4°C) tor 15 
minutes. The RNA formed a white-yellow pellet at the bottom of the 
tube. The supernatant was then removed with a micro-~ipette and the 
pellet washed in 500ul of 75% ethanol, by vortexing and subsequent 
centrifugation at 71 OOrpm (4°C) for 8 minutes. The 75% ethanol was 
removed and the RNA pellet was dried under vacuum for 10 minutes. 
Finally, the dried RNA was resuspended in 50ul of double distilled 
water (DOW). 
2.2.2 Modified GuHCI RNA Extraction 
. This method of RNA extraction is described in Chirgwin et al (1979) 
and requires more preparation and time than the RNAzol method. The 
first step involves making up the three solutions required in the 
extraction procedure. 
2.2.2.1 Solutions For RNA Extractiol)· 
Solution 'A' 
Solution 'B' 
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6M . ' GuHCI 
200mM 
10mM 
6M 
200mM 
10mM 
NaAc pH 5.'2'- 6.0 
B-ME 
GuHCI 
NaAc. pH 5.2 - 6.0 
EDTA 
Solution 'C' 7M 
100mM 
Urea 
Tris pH 8.0 
200mM NaAc pH 5.2- 6.0 
0.5% . SDS 
10mM EDTA 
2.2.2.2 GuHCI RNA Extraction Procedure 
The volumes of each solution required for the extraction of RNA are 
based on a starting muscle sample of 5 to 1 Omg. Throughout the RNA 
' 
extraction the samples and solutions were kept on ice, whenever 
possible . 
. The muscle sample was homogenised in a 1.5ml reaction tube, with 
500ul of solution 'A', then 500ul of 100% ethanol was added. This 
solution was then mixed well and chilled at -80°C for 15 minutes. The 
sample was then spun at 13650g (4°C) for 15 minutes, the 
supernatant discarded and the pellet resuspended in 300ul of solution 
'6'. The pellet was then homogenised again in solution '6', after which 
. 
300ul of 100% ethanol was added. Tlils solution was then mixed well 
and chilled at -B0°C for 15 minutes. Next, the sample wci's then spun at 
13650g (4°C) for 15 minutes, the supernatant was discarded and the 
pellet resuspended in 400ul of solution 'C' alter which 400ul of 
buffered phenol and 400ul chloroform:isoamyl alcohol_ 24:1 was added 
to the pellet in solution 'C'. This solution was mixed well and left on ice 
for 10 minutes. Spinning the solution at 13650g. (4°C) for 15 minutes 
resulted in two phases, w~h the top aqueous phase containing the 
RNA. This top aqueous phase was transferred to a fresh 1.5ml reaction 
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tube containing 800ul of 100% ethanol. The ethanol and RNA 
aqueous phase were mixed well and chilled at -20°C overnight. The 
following day, the aqueous phase with ethanol was spun at 136SOg 
(4°C) for 1S minutes and the supernatant discarded. The RNA pellet 
was washed in 300ul of 70% ethanol, the 70% ethanol removed and 
the pellet dried under vacuum. The RNA pelle.t was then resuspended 
in SOul of DDW. 
2.2.3 eDNA Synthesis from mRNA 
Reverse transcription is the process of converting single stranded 
mRNA into double stranded eDNA using the retroviral enzyme reverse 
transcriptase. This eDNA doesn't include any intronic sequence as this 
was spliced out of the mature mRNA (Sambrook et al, 1989). 
Using the RNA extracted by the RNAzol or modified GuHCI methods, 
4ul of RNA was added to 4 units of AMV-RTase, 2SOng of random 
hexamers, Sui of Sx buffer as supplied by Promega and then the 
reaction was brought to volume with DOW. The reaction was then 
incubated for 5 minutes at room temperature followed by 60 minutes at 
42°C. The eDNA was then diluted 1:20 in DDW and stored at 4°C. 
2 .2)1 Gel Electrophoresis 
,. 
• 
DNA and RNA migrates according to descending size, from the 
.. 
cathode (-ve) towards the anode (+ve) in response to an electric 
current in either an acrylamide or agarose gel. In order to increase 
separation of the different sized DNA and RNA it is necessary to vary 
the gel concentration, running time and voltage (Sambrook et al, 
1989). 
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2.2.4.1 Making Agarose gel 
Increasing the agarose concentration makes for a denser gel. The 
greater the agarose concentration, the slower the DNA travels through 
the gel matrix. Also the size of the DNA sample being fractionated 
determines the agarose concentration needed, the smaller the DNA 
sample the greater the concentration of agarose required (Sambrook 
et al, 1989). 
1% Agarose gel 
1g ofagarose in 100ml of 1x TAE butter 
· 2% Agarose gel 
2g of agarose in 1 OOml of 1 x TAE buffer 
3% Agarose gel 
3g of agarose in 100ml of 1x TAE buffer 
Agarose and 1 x TAE buffer were added to ~·stock bottle, with the lid on 
locis~ly. The solution was boiled in a,microwave oven and agitated 
until all the agarose had dissolved, then stored in a d'Y"oven at 65°C 
until ready to pour. 
2.2.5 Running RNA on Agarose gel 
A 1% agarose solution was poured onto a gel tray to a depth of 5 to 
10mm. A gel comb was then placed in the solution, 1cm in from one 
end and to a depth of approximately 1 mm from the l)ase of the tray. 
The agarose solution was then left 15 minutes at room temperature to 
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set. Once set, the comb was removed and the gel placed in a gel tank 
with 1 x TAE buffer covering the gel. 1 Oul of the RNA sample, along 
with 2ul of ficoll loading buffer (6x), was loaded into each well. The gel 
was then run for 45 minutes at 1 00 volts(v) and stained with ethidium 
bromide, which binds to DNA/RNA. After staining, the gel was 
observed under an ultra-violet (UV) light (305nm Transilluminator), 
which fluoresces the DNA and RNA. 
2.3 Results 
The RNA extraction was carried out using two methods, (i) RNAzol 
system and (ii) modified GuHCI method. The RNAzol method, although 
very quick (total extraction of RNA in less than three hours) did not 
yield RNA of sufficient size and quantity as subsequent nested PCR 
analysis showed. In Figure 2.1 the "RNAzol1" and "RNAzol 2" lanes 
. show faint bands, indicative of 18s ribosomal RNA. The second 
method of RNA extraction was a modified GuHCI method (Chirgwin et 
al, 1979). This method also extracted DNA. The "GuHCI1" and "GuHCI 
2" lanes in Figure 2.1 shows the DNA extracted with no sign of RNA. 
However, PCR analysis showed this RNA extraction procedure worked 
well. A third method of RNA extraction, a·hybrid of RNAzol and the 
modified GuHCI methods was tried iri 'the hope of providing a taster 
and more efficient method of extracting RNA. This 11fethod did not 
prove successful, as the yield of RNA was not sufficient to allow further 
nested PCR analysis (data not shown). 
eDNA synthesis was achieved using AMV-RTase. The conditions 
remained constant for all RNA transcripts whether extracted by RNAzol 
or the modified GuHCI method. It was only after the arr1plificatlon stage 
of the eDNA by PCR that it was possible to determine whether the RNA 
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Figure 2.1 
A 1% agarose gel loaded with 1 Out aliquots of the RNA 
extracted from normal muscle by the RNAzol and GuHCI 
i 
·methods. The numbers 1 and 2 for RNAzol and GuHCI 
represent two different muscle samples, which are normal for 
dystrophin. The bands in sample GuHCI 1 and GuHCI 2 
. represent DNA extracted in this procedure. Lamda marker 
digested with Pst I. 
... 
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Lambda Marker 
RNAzol 1 
RNAzol 2 
GuHCl 1 
GuHCl 2 
Lambda Marker 
extraction and the eDNA synthesis actually worked. The best method 
of extracting RNA from small amounts of frozen tissue proved to be the 
GuHCI method although it was more time consuming than the RNAzol 
method. 
Extraction of RNA from 5 to 1 Omg of muscle tissue resulted in very few 
RNA transcripts. It was not possible to determine the presence of tRNA 
and rRNA by running an aliquot of the RNA on a 1% agarose gel (see 
Figure 2.1 ). All RNA samples were converted to eDNA (reverse 
transcription), in order to perform further analysis. This was done 
because PCR amplification requires only a few full length transcripts to 
, produce multiple copies of eDNA required for further analysis. 
2.4 Discussion 
Factors that influence the quality of RNA extraction include the type of 
sample, storage of the sample and the extraction procedure. As 
muscle samples from affected DMD/BMD patients were in such small 
quantities, it was necessary to optimise the extraction procedure by 
trying various RNA extraction techniques on normal muscle samples 
which had been stored in the same manoer as the affected muscle 
samP.Ies (-80° C). Once the RNA extra9tion and eDNA synthesis were 
optimised it was then decided to proceed with the aff.~cted samples. 
Three methods of RNA extraction were tried on normal muscle 
-
samples, (i) RNAzol (ii) modified GuHCI and (iii)a hybrid of RNAzol 
and GuHCI methods. The RNAzol method and the hybrid 
RNAzoi/GuHCI methods when used on small amounts of frozen tissue 
(5-1 0 mg), did not provide sufficient good quality mRNA to do further 
PCR analysis using the nested primers specified by Atlbs et al (1991). 
The modified GuHCI method was able to produce RNA of sufficient 
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quality to allow further PCR analysis. When this RNA was extracted 
and an aliquot was run on a 1% agarose gel to determine (i) whether 
there was RNA present and (ii) if it was present whether it was 
degraded. The small amounts of tissue being used 5-10mg in these 
RNA extraction procedures, did not produce sufficient RNA for the 
bands to be visualised. RNA when run on an agarose gel should give 
three prominent bands, representing 5s, 18s and 28s ribosorotal and 
transfer RNA (Alberts et al, 1983 p.209). It was necessary to go on and 
produce the eDNA and do a nested amplification in order to determine 
whether the RNA extraction had worked efficiently. 
, Not all DMD/BMD patients will submit to a biopsy, therefore, although 
muscle may provide the most abundant quantity of dystrophin mRNA 
transcript (Chelly et al, 1988), it is possible to obtain dystrophin mRNA 
from lymphocytes (Roberts et al, 1990). This may prove to be a much 
more practical when looking for mutations in other Western Australian 
dystrophic families. 
,. 
... 
,. 
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CHAPTER 3: NESTED AMPLIFICATION 
3.1 Introduction 
Polymerase chain reaction (PCR) is a new development in DNA 
technology, with the ability to amplify a short sequence of DNA from a 
complex mixture containing:-
1) Target DNA 
2) Taq Polymerase 
3) 5x mix (buffer, nucleotides and 
MgCI2) 
4) 
5) 
Primer 
6) Paraffin overlay (stops evaporation) 
It is first necessary to synthesise two short oligonucleotide primers 
based upon the known sequence of the region. These primers are 
chemically synthesised and are usually between 20-35 nucleotides 
long. Polymerase chain reaction takes place by heating the target 
DNA, which denatures it int.o single strands. The reaction is then 
cooled to a preset annealing tempe:rature which allows the 
oligon"ucleotide primers, present in high concentration, to anneal to 
their complementary DNA strands (Bej, 1991 ). Once annealing is 
completed, extension of the DNA occurs with nucleotid"s being added 
to the primer by the enzyme Taq polymerase. The Taq enzyme is able 
to withstand temperatures as high as 95°C and is derived from a 
bacteria found in hot springs (Thermus aquaticus) (Erlich, 1989). 
Extension only occurs when the primers anneal to the target DNA, 
which then allows the Taq polymerase to synthesise a DNA strand 
using the target DNA as a template. This whole procedure is easily 
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cycled, with each cycle taking about 5 minutes and the synthesised 
product in one cycle can serve as a template in the next. At the 
completion of each cycle the DNA sequence specified by the primers, 
will have doubled. As many as 30 to 40 cycles can be carried out 
without the need to add fresh enzyme or primers. 30 cycles results in 
approximately 1 billion copies of the target DNA and all this occurs in a 
single PCR tube (Gelehrter & Collins, 1990, p. 82). 
Nested amplification is a modified PCR. It involves two sets of primers, 
used in two separate PCR reactions. The first reaction is a standard 
PCR, usually carried out for 30·35 cycles. The nested amplification, 
uses primers which are internal to the first round primers. It also uses a 
diluted first round amplification product as target DNA in the nested 
amplification. The product that results is the same size as one obtains, 
when only the nested primers and the original target DNA are used in 
/ 
· ' a PCR reaction (see Figure 3.1) (Roberts et al, 1991 ). 
The nested amplification method provides both a double check on the 
sequence being amplified and results in a much more specific 
amplification. The conditions of amplification are not extremely 
stringent, but because the second round amplification is of a product 
-
slightly smaller and contained within ihe first round amplification, this 
increases the specificity of the bands produced. • 
.. 
The nested PCR method of amplification is able to amplify up 
extremely small amounts of the template DNA billions of times, if the 
eDNA produced by reverse transcription was of suffiCient quality. It is 
then possible to run the amplified DNA on an agarose gel and after 
ethidium bromide staining, visualise it under a UV li~ht (Bej, 1991). 
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Figure 3.1 
Nested Amplification: The eDNA is amplified primarily with a 
primer mix consisting of primer A and D, this amplified product 
' 1s then diluted and used as target for the nested amplification. 
A primer mix consisting of primer B and C is then used in the 
nested amplification, this nested product can then be 
electrophoresed on an agarose gel, stained with ethidium 
bromide and viewed under a UV light source . 
.. 
... 
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Primer C 
Primer D 
5' 3' 
3' 5' eDNA 
Primar A 
Primer B 
roduct 
Prima roduct 
The accuracy of PCR analysis depends upon a number of factors 
including the quantity of template, the concentration of the dNTP's, 
primer concentration, Taq Polymerase concentration and MgCI2 
concentration (Innis et al, 1990). The conditions used in the nested 
PCR and all the other PCR reactions were choscln in order to minimise 
the chance of mis·incorporation during amplification. 
3.2 Materials and Methods 
All PCR reactions used the following 5x Amplification mix unless 
olherwise stated. 
The 5x Amplification mix consists of:-
1mM dNTP 
5x Reaction Buffer (Biotech) 
10mM MgCI2 
Reaction Concentration:-
3.2.1 
.. 
200uM dNTP 
1 x Reaction Buffer (Biotech) 
2mM MgCI2 
Amplification of dilute ci>"NA 
•·· 
Amplification of the eDNA (dilute) involved a primary amplification with 
. 
external primers. This reaction was subsequently diluted 1 :200, so as 
to reduce carry over effect of external primers, with DDW and a Sui 
aliquot used in the secondary amplification in which p·rimers internal to 
the primary amplification primers were used. The approximate length 
of the final amplified product was 1250 bp. This procequre is known as 
nested amplification. Table 3.1 indicates the primers used in order to 
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Table 3.1 
Primers used in nested amplification 
Sequence (5' to 3') Primary/Nested Position Exon 
ATGCTTTGGTGGGAAGAAGTAG p 208·230 2·10 
GAGAGGTAGTTACTTGACGGT p 1197·1218 2·10 
TTATGAAAGAGAAGATGTTCAA N 237·259 2·10 
i CTTGTCTTCAGGAGCTTCCAA N 1171-1192 2·10 
CGATTCAAGAGCTATGCCTAC p 1091·1111 9·18 
GCGAGTAATCCAGCTGTGAAG p 2399·2419 9·18 
CCTCTGACCCTACACGGAGC N 1134·1153 9·18 
CAGTTATATCAACATCCAACC N 2376·2396 9·18 
CATGCTCAAGAGGAACTTCC p 2300·2319 17·25 
CTGAGTGTTAAGTTCTTTGAG p 3599·3619 17·25 
GCAGATTACTGTGGATTCTG N 2344·2363 17·25 
GTCTCAAGTCTCGAAGCAAAC N 3574·3594 17·25 
CTAGAAATGCCATCTTCCTTG p 7583·7603 51·58 
CTCAGGAGGCAGCTCTCTGG p . 8871-8890 51-58 
.. 
CTG¢TCTGGCAGATTTCAAC N. 7617-7636 51-58 
CTCCTGGTAGAGTTTCTCTAG N 8849-8869 51-58 
-------~~--------------------------------------------------------------------------------------
• 
·(Roberts et al, 1991) 
e 
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do the nested amplification of exons t-10, 9-18, 17-2S, St-SB. All 
primers were synthesised at this laboratory on a Cyclone Plus DNA 
Synthesizer (Milligan I Biosearch). 
3.2.2 Primary amplification of the dystrophin transcript 
To a O.Sml PCR tube was added Sui of Sx buffer, t3.Sul DDW, 1 ul of 
the outer primers (70ng), O.S units of Taq polymerase (Biotech) and Sui 
of dilute eDNA. The reaction mix wa~ .hdn vortexed for one second 
and a drop of paraffin added to overlay the reaction. The primary 
amplification was for 3S cycles of 94°C for 30 seconds, 5S°C for 1 
, minute and 72°C for 2 minutes (the initial denaturation step at 94°C 
was carried out for S minutes). At the end of the primary amplification 
the PCR product was diluted 200 fold by adding DDW to the PCR tube 
and then vortexing. This provided the target for the secondary 
amplification. 
3.2.3 Nested amplification of the dystrophin transcript 
The second round polymerase chain reaction was essentially the 
same as the primary amplification except_ ·sui of the diluted primary 
amplification mix was used as the target instead of the Sui of dilute 
. . ' 
cDNA,.that was used in the primary amplification. Also _jhe number of 
• 
cycles used in the secondary amplification was reduced to 30 cycles. 
3.2.4 Molecular weight markers 
In order to determine the size of the DNA fragments during gel 
electrophoresis it was necessary to run standards which indicate the 
approximate size of the DNA samples run on the gel.. Lambda phage 
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when cut with the restriction enzyme Pst I provided a high molecular 
weight marker and pUC 19 cut with Msp I provided a low molecular 
weight marker (see Figure 3.2). 
3.2.4.1 Lambda cut with Pst I 
To a 1.S ml reaction tube was added; 1SOul of 1 Ox buffer "3", 30ul of 
0.1 M spermidine, 1Sul of 1 Omg/ml BSA, 9ul of 20 units/ul Psi I 
enzyme, 996ul of DOW and 300ul uncut lambda 500ng/ul. The tube 
was then vortexed lightly and incubated for 8 hours at 37°C to allow 
digestion to take place. The lambda cut with Psi was then ethanol 
precipitated and resuspended in 6ml of Fico II 1 x loading buffer. Sui of 
marker was loaded on all agarose gels. 
3.2.4.2 pUC 19 cut with Msp I 
, To a 1.S ml reaction tube was added; 1SOul of 10x buffer "A", 30ul of 
0.1 spermidine, 1Sul of 1 Omg/ml BSA, 9ul of 20 units/ul Msp I enzyme, 
996ul of DOW and 300ul of uncut pUC 500ng/ul. The tube was then 
vortexed lightly and incubated for 8 hours at 37°C to allow digestion to 
take place. The pUC cut with Msp I was then ethanol precipitated and 
resuspended in 1.5ml of Fico II 1 x loading buffer. The DNA 
. ··:. 
concentration was much less than sbong/ul, due to the presence of 
RNA in the uncut pUC sample. The RNA in the pUC safijple resulted in 
a much greater DNA reading when measuring absorbance at 260nm 
in a spectrophotometer. Sui of the marker was loaded on all agarose 
gels. 
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' Figure· 3.2 
Molecular weight markers: Lambda cut with the enzyme Pst I 
(High molecular weight marker) and pUC 19 cut with Msp I 
·(Low molecular weight marker). 
,. 
,·· 
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Lambda cut with Pst I 
- 11500 
4789 . 4749 
2556 . 2443 - 2838 
1886 - 2190 
-- 1700 Number of 
1159 Base Pairs 
1093 
805 
-
468 - 514 
-
- 448 
339 -
pUC cut with Msp I 
501 . 489 
- 404 
- 331 
Number of 
- 242 Base Pairs 
-
190 
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-
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3.2.5 Electrophoresis of nested products 
The nested amplification products were run on a 2% agarose gel, for 
one and a half hours at 100 volts in 1 x TAE buffer. 2ul of the sample · 
was mixed with 2ul of fico II loading buffer (1 x) and loaded to each 
lane. The gel was visualised by staining with ethidium bromide, which 
will fluoresce the DNNRNA under UV light (305nm Transilluminator). 
3.3 Results 
Figure 3.3 shows the nested amplification of eDNA, exons 1 to 10, 
derived by reverse transcription of RNA extracted using GuHCI method 
, on normal muscle samples. Figure 3.3 is also evidence that the RNA 
extraction and eDNA synthesis worked with normal muscle samples 
(no known deletions). Although the primary amplification lanes in 
Figure 3.3 samples show no evidence of any amplified product, there 
is an ion front which is a characteristic of the loading buffer that was 
used. Subsequent dilution of this primary amplification product 
followed by nested amplification resulted in a strong signal for the 
nested products corresponding to exons 2 to 10 of the dystrophin 
gene. 
Figure 3.4 shows the nested amplified products of seven individuals 
from different families (A- G) who have point or minor mutations in the 
dystrophin gene. Amplification of exons 9-18 show patient D as having 
no product, this is consistent with the amplification:of exons 17-25 and 
51-58 which also indicate no products for patients D (see Figure 3.4). 
This indicates either the RNA extraction or the eDNA synthesis hasn't 
worked, or that this patient lacks all these exons. As patient D has 
already been tested using conventional southern blot· analysis, which 
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Figure 3.3 
Nested amplification of exons 2 to 1 0 from eDNA normal for 
dystrophin. 1 and 2 signify two different eDNA samples, which 
are normal for the dystrophin gene. Amplification was done 
using nested primers to amplify exons 2 to 10 of the dystrophin 
·gene. The samples were run on a 2% agarose gel at 1 00 volts 
for 1 hour. Lambda marker digested with Pst I. 
,. 
• 
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Lambda Marker 
Primary Amplification 1 
Primary Amplification 2 
Nested Amplification 1 
Nested Amplification 2 
-ve Control 
Lambda Marker 
Figure 3.4 
Nested amplification of eDNA derived from patients from 
different families who have either DMD or BMD. A to G signify 
different patients, the exons amplified for each of these 
patients are 9-18, 17-25 and 51-58 respectively. The samples 
were run on a 2% agarose gel at 100 volts for 1 hour and 15 
minutes. Lambda marker digested with Pst I. 
,. 
. ..
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did not indicate any major deletions, it was therefore assumed that the 
RNA extraction or eDNA synthesis had not worked. No product is 
evident for patient E exons 51-58 (see Figure 3.4). As the eDNA of 
patient E amplified exons 9-18 and 17-25 this would indicate either; 
that the eDNA transcript for exons 51-58 was not in sufficient quantity 
to provide a target in the primary amplification, there was human error 
in the setting up of the ampliiication, there was a mutation in the primer 
binding sites, or a major deletion of exons 51 to 58. A major deletion of 
this size would have been picked up using conventional southern blot 
analysis. Excessive amplification of exons 51-58 for patients (A to G) 
has resulted in a strong signal for all patients, with some non-specific 
bands. Figure 3.4 shows patient G as having two distinct bands for 
exons 17-25, one band corresponding to the normal sized product and 
also a smaller product which is of the same intensity yet approximately 
90 bases smaller. 
3.4 Discussion 
It was shown in Figure 3.3 that by using nested amplification it is 
possible to amplify small amounts of target. Although at the end of 
primary amplification no signal is evident, this primary amplified 
-
product was then diluted prior to being used as target DNA for the 
" .. 
nested amplification. As noted earlier in 3.2.1 dilution lakes place so 
that the primary amplification primers do not interfere :in the nested 
amplification otherwise this could result in a second larger product 
specified by the external primers also being amplified. 
When nested amplification of seven individuals (figure 3.4; A to G) 
who had either DMD or BMD was done using primers that amplified 
exons 9-18, 17-25 and 51-58 of the dystrophin gene, it was evident 
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that patient G had two amplified products for exons 17-25, one a 
normal size product and a second product approximately 90 bp 
smaller. The doublet band in Figure 3.4 patient G, exons 17-25 
indicates that the two transcripts are found in equal volume in the 
muscle. Dr Steve Wilton showed by repeating this nested reaction with 
a decrease in the number of PCR cycles that the quantity of the 
alternately spliced transcript was approximately nine fold higher than 
the normal transcript (data not shown). In order to reduce the non-
specific banding in Figure 3.4 and give a clearer quantitative indication 
of both transcripts, it would be necessary to reduce the number of 
cycles either in the primary or secondary amplification or increase the 
' dilution of the primary amplification, prior to using it as target in the 
nested amplification. 
Exon 19 is 88 bp long and it was considered a good location for 
looking for a mutation, as all the other exons from 17 to 25 were over 
1 00 bp (Koenig et al, 1988). 
It is also important to note that not all muscle samples from the affected 
DMD/BMD patients were able to be amplified using nested PCR. This 
indic~tes the difficulty of trying to extract RNA and then produce viable 
eDNA in order to amplify transcripts of the dystrophin gene, which are 
over 1'2oobp. • 
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Chapter 4: SEQUENCING 
4.1 Introduction 
The nested amplification of exons 17-25 indicated that the mutation in 
patient G was under 100 bp. Analysis of the eDNA transcript for exons 
17 to 25 indicated exon 19 as an ideal location to search for this 
mutation as it was 88bp, while all the other exons in the moe. were 
over 1 00 bp (Koenig et al, 1988). It was decided to sequence exon 19 
and part of intron 18 and 19, from genomic DNA in an attempt to 
determine the site of the mutation. The entire sequence of the eDNA 
transcript for the dystrophin gene is known (Koenig et al, 1988), 
making comparison of our exon sequences with the normal transcript 
easy. It was also necessary to sequence genomic DNA from a patient 
who is normal for dystrophin, in order to determine differences in 
intronic sequence that may also have occurred. 
The Sanger sequencing method involves using four separate stop 
reactions, one for each nucleotide 'A', 'C', 'G', 'T', in four separate PCR 
reactions. Included in the 'A' stop reaction are the normal dinucleotide 
triphosphates (dNTP's). which are required for normal amplification 
reactions, with the addition of dideoxynucleotide ATP (ddATP) 
(Gelehrter and Collins, 1990, p. 87). In the 'A' stop reaction the end 
labelled primer anneals to the target DNA and the complementary 
strand is synthesised using Taq Polymerase. When the ddATP is 
incorporated into the growing chain, during PCR, synthesis of that 
molecule stops. The ddATP is randomly incorporated into the growing 
chain producing amplified products of different sizes, dependant on 
when the ddATP is incorporated during each PCR cycle. The same 
process takes place for the other three nucleotide stop reactions ('C', 
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'G', 'T'), but these reactions have dideoxynucleotide CTP (ddCTP), 
dideoxynucleotide GTP (ddGTP), dideoxynucleotide TTP (ddTTP) 
respectively, to stop each reaction (Gelehrter and Collins, 1990, p.87). 
The four stop reactions, if run in separate lanes on a polyacrylamide 
gel and then exposed to X-ray film, will produce a ladder of oligomers 
of different lengths from which the DNA sequence can be read. 
Reading from the bottom of the gel upwards, each band represents the 
complementary base found on the target DNA moving in a 5' to 3' 
direction away from the primer (see Figure 4.1) (Erlich, 1989). 
The Genesis sequencing system (Biotech) was chosen because of its 
simplicity in setting up the four stop reactions. The inclusion of a single 
dideoxynucleotide in each of the stop reactions effectively terminates 
the DNA chain elongation at the base complementary to the ddNTP. 
This is due to the ddNTP lacking the 3'-0H group that is necessary for 
continued chain elongation (Watson et al, 1987, p. 276). The use of 
PCR in the sequencing increases the speed and sensitivity of 
sequencing. 
4.2 Materials and Methods 
A 500ml stock of 6% denaturing acrylamide solution, for sequencing, 
was made by adding; 28.5g acrylamide, 1.5g bis-acrylamide, 21 Og 
urea and 425ml DDW to a beaker and the contents stirred until all the 
reagents were dissolved. Once dissolved, 40g of mixed bed resin was 
added and stirred slowly for 30 minutes at room temperature. A funnel 
and filter paper were then used to filter the acrylamide from the mixed 
bed resin. DDW was then added to the mixed bed resin and filter to 
bring the volume of acrylamide up to 450ml. Fin811y, SOmis of 1 Ox TBE 
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Figure 4.1 
"The DNA sequencing method developed by Sanger. Using a 
primer homologous to one end of the DNA strand to be 
sequenced, the complementary strand is synthesized using 
DNA polymerase. Small amounts of dideoxynucleotide 
(ddATP, ddCTP, ddTTP, ddGTP) are included in four separate 
such reactions; when a dideoxynucleotide is incorporated into 
a growing chain, synthesis of that molecule stops. Separation 
of the resultant labelled fragments in four lanes of a 
polyacrylamide gel, followed by exposure to X-ray film, allows 
the sequence to be read off directly" (Gelehrter and Collins, 
1990,- p. 87). 
49 
GEL 
ELECTROPHORESIS 
AUTofiA.oioGRAPiiY 
.:·-TO DETECT--.--
RADIOAcnvE BANDS 
~ • • !'; ~ t ~ 
" ~ 
~ ~ ~ ~ ~ ~ ~ 
LARa·E~·-·. 
-
-
-
FRAGM~:;!~:> 
-
-
. 
-
-
-
-
5' 
SJNGLE·STRANOED DNA 
_OF UNKNOWN SEQUENCE 
CTGACTTCGACAA ~ 3, 
RAOJOACTJVELYLABELEO , T G T i___.e:'\. 
'PAlMER 3 ~S' 
DNA POi. VMERASE J 
dATP 
"(j-0 -CHr.:-O:!lASE 
HHH dGTP 
dCTP 
dTIP 
H H 
OJDEOXYNUCLEOTJDE {ddNTP) 
ddATP ddCTP ddTIP ddGTP 
C T G 
REACTION 
MIXTURES 
A C T T C 
ddGO 
ddGO 
G A C A A 
• 
~· I ddGo---------------~~· 
c 
T 
G 
A• 
c 
T 
T 
c 
G 
PRODUCTS JN ddGTP REACTION 
, . :::t~:~<;~~~ig~z:IGJNAL 
, (COMPlEMENT OF PRIMER· 
GENERAJ:ED SEQUENCE LADDER) 
was added to the acrylamide mix which was then stored at 4°C in a 
bottle wrapped in aluminium foil. 
4.2.1 6% Denaturing acrylamide gel for sequencing 
SOmis of 6% denaturing acrylamide solution was prepared to pour a 
Poker Face acrylamide gel for sequencing analysis. 
SOmis of the 6% denaturing acrylamide stock solution was added to a 
1 OOml beaker. 170ul of TEMED and 170ul of 25% ammonium 
persulphate (APS), which had both been stored at 4°C, were added to 
the beaker and mixed gently. The TEMED and the 25% APS catalyse 
the polymerisation of liquid acrylamide into gel acrylamide within 5 
minutes. The acrylamide solution was then drawn up in a 1 OOmi 
syringe and injected between the two glass plates used in the Poker 
Face electrophoresis system (Hoefer), making sure not to leave air 
bubbles between the plates. The comb was then inserted 
approximately 5 to 1 Omm into the gel mix. Once the gel had formed, a 
moist piece of paper was placed over the comb and the top of the gel 
wrapped in gladwrap to keep in the moisture. This gel was then stored 
at room temperature for up to one week. 
4.2.2 Cycle sequencing (Biotech) 
The Biotech Genesis sequencing kit provided a simple and effective 
means of analysing DNA sequences. The sequencing protocol was 
carried out according to the Biotech Genesis informaf1on pamphlet with 
some slight modifications. The volume of sterile water was reduced to 
14.25ul, 2.25ul of template DNA was used which is approximately 
20ng of DNA and only 1.5ul of end labelled primer was used. These 
changes in the Biotech protocol were made to rectify the master mix 
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concentrations, which were incorrect in the Biotech protocol pamphlet. 
All solutions except for the end labelled primer and target DNA 
wereprovided in the Genesis sequencing kit. Genomic DNA was 
extracted from lymphocytes (Jacobsen, 1992). The end labelled primer 
was donated by Dr Steve Wilton. This primer sequence was specified 
by Abbs et al, (1991) and designated primer sequence:-
(19 F)orward [ 5' TICTACCACATCCCATTTTCTTCCA 3'] 
Four 0.5ml PCR tubes were labelled A, C, G, T, and then 4ul of each 
stop mix was added to the appropriate tubes. The tubes were then 
placed on ice until required. Next, a master mix was made up in a 1.5 
ml reaction tube, by adding in order the following components: 
14.25ul DDW, 1 Oul 5x sequencing buffer, 2.25ul of template DNA 
(20ng), 1.5ul of end labelled primer (30ng/ul) and 2ul of Taq 
polymerase (2units/ul). The master mix was gently mixed and Sui 
transferred to each of the four stop mixes. Then each of the stop 
reactions was overlaid with one drop of paraffin oil. The four stop 
reactions were then placed in a thermal cycler and the following 
program was run :-
94°C for 2 minutes x1 
94 °C for 30 seconds x20 
55°C for 30 seconds 
70°C for 1 minute 
94°C for 30 seconds x1 0 
70°C for 1 minute 
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Sui of Formamide loading buffer was then added to each of the stop 
reactions ("A", "C", "G", "T") through the paraffin overlay and gently 
mixed by pi pelting up and down. 
4.2.3 Running sequencing gel 
The sequencing products from the Genesis system were fractionated 
on a 6% denaturing polyacrylamide gel, using the Poker Face 
electrophoresis system. 
The 6% denaturing polyacrylamide gel was pre-run (to warm gel to 
45°C) for 30 minutes in 1x TBE buffer at 1400 volts and the lanes 
marked before the comb was taken out. The lanes were then flushed 
out with the 1 x TBE, using a syringe, in order to remove urea and 
bubbles from the wells. Stop mixes made using the Genesis 
sequencing kit (Biotech) were incubated at 94°C for 5 minutes and 2ul 
of each stop mix ("A", "C", "G", "T'') was loaded into consecutive lanes. 
The gel was then run at 1400 volts for 4 hours. 
4.2.3.1 Fixing, drying and exposing polyacrylamide gels. 
The polyacrylamide gel was then fixed in a 10% acetic acid, 10% 
methanol solution, by pouring 1 litre of the fixative over the gel in 15 
' 
minutes. Once the gel was fixed it was removed from the glass plate 
with 3mm blotting paper. The blotting paper was placed on the gel and 
lifted off taking the gel off the glass plate. Gladwrap was carefully 
placed over the gel. The gel was then put in a gel dryer (Hoefer) for 3 
hours at 80°C at which time the gel had dried to the 3mm blotting 
paper. An X-ray film (Cronex 4 - DU PONT) was then exposed to the 
gel for 1 0 to 24 hours at -80°C, dependant on how much 32P was in 
the reaction, with an intensifying screen. 
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4.3 Results 
In Figure 4.2 there is some cross-banding close to the mutation site 
making some of the sequence hard to distinguish. The "A" to ··c·· base 
change is clearly visible and had the gel been allowed to run further, 
this would have increased separation of the relevant area. Initially 
though, it was not known exactly where the mutation would lie (if it was 
present at all), therefore this gel provided the first indication of the point 
mutation. At the bottom of Figure 4.2 the sequence separation is much 
greater and easier to read and so in subsequent sequencing of the 
mutation the gel was run much further. In order to confirm the mutation 
at the 5' end of intron 19, one base 3' to the universally conserved 
donor splice site, the complementary strand of genomic DNA was 
sequenced, by Dr Steve Wilton. This indicated a "T" normal for 
dystrophin changed to a "G" in the BMD patient. This provided 
supporting evidence for a mutation in the consensus sequence at the 
5' end of lntron 19. 
4.4 Discussion 
Sequencing of genomic DNA of a subject normal tor dystrophin and 
patient G with BMD indicated an "A" to "C" change shown in Figure 4.1. 
This indicates a mutation at the 5' end of lntron 19, one base pair 3' to 
the universally conserved "G", "T" donor splice site, but in the donor 
consensus sequence, necessary for splicing to occur (see Figure 4.3). 
Mutations at the donor (5' end of intron) and acceptor (3' end of intron) 
splice sites of genes have been shown to produce varied effects in the 
formation of mature mANA, including the complete exclusion of exons, 
as seen in patient G with BMD. 
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Figure 4.2 
Sequencing of normal and affected (Patient G) genomic DNA 
on a 6% denaturing acrylamide gel. The mutation is evident at 
the base after the universally conserved donor splice site "GT"' 
' 
and results in an "A" to "C" mutation in the affected individual. 
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Figure 4.3 
Sequencing information derived from the normal and BMD 
patients. " • " indicates the site of the mutation, while the arrow 
delineates the exon intron boundary. 
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5' l Exon 19 lntron 19 3' 
TGGAACAAGATGGTGAATG GTAA TT ACACGAGTTGA TtT AGATA Normal sequence 
• 
TGGAACAAGATGGTGAATG GTCA TT ACACGAGTTGA TTT AGATA BMD sequence 
AG GT AAGT Consensus splice site 
;{;, G T A A'S'""'"" 
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Rees et al (1985), showed in a haemophilia B patient, that the only 
significant sequence difference occurred at a donor splice site and 
consisted of a single base substitution of a "G" to a "T". Cladaras et al 
(1987), showed that an "A" to "G" substitution in the acceptor splice site 
of the third intron of a deficient Apo·E gene can cause aberrant 
splicing of the third intron. This aberrant splicing led to two mature 
mANA's containing either a portion or the entire 3rd lntron of the Apo·E 
gene. Cladaros et al (1987), also mentions a similar "A" to "G" 
substitution of the second intron of the B globin gene. This mutation, 
however only generates a single larger size B globin mRNA that 
contains a portion of the second intron. 
Mounir et al (1990), showed that a mutation at the JH6 Donor splice 
site in the JBL2 gene causes Burkitts Lymphoma. Splicing therefore 
occurred at an alternate splice site which was 5' to the normal Donor 
splice site. Carstens et al (1991 ), identified two point mutations in the 
Ornithine Transcarbamylase (OTC) gene which is an X-linked 
recessive gene like DMD and BMD. One patient who had deficiency of 
OTC had a "T" to "C" substitution at the Donor splice site of intron 7, 
this substitution caused exon 7 to be skipped (see Figure 4.4). This 
mutation is similar in effect to the mutation described in our BMD 
patient, both are mutations of the donor consensus sequence although 
the OTC mutation is at the donor splice site, which results in the 
previous exon being skipped. Another patient had an "A" to "T" 
substitution at the Acceptor splice site, at the end of lntron 4. This led to 
a cryptic 3' Acceptor splice site being formed in exon 5 resulting in a 
deletion of 12 bases in the mature mRNA. 
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Figure 4.4 
Ornithine transcarbamylase gene: A single base mutation, at 
the universally conserved donor splice site of intron 7, results 
in exon 7 being skipped in the mRNA transcript (Carstens et al, 
1991 ). Note that the universally conserved donor splice site is 
GU as compared to GT in DNA. 
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Takahaski et al (1990), working with the p53 tumor suppressor gene 
showed that point mutation at the acceptor and donor splice sites can 
both result in the inactivation of p53 tumor suppressor gene. A point 
mutation at the acceptor splice site "G" to "C" at the 3' end of intron 3 
can generate two forms of mature mRNA. The first form uses a cryptic 
acceptor splice site in Exon 4, therefore producing a mRNA with part of 
exon 4 incorporated. The second form uses the normal acceptor splice 
site at the 3' end of lntron 4. This results in mRNA which has exon 3 
connected to exon 5 ie. the complete exclusion of exon 4. The other 
mutation noted by Takahashi et al (1990),was a point mutation at a 
donor splice site of intron 7, a "G" to a "T". This resulted in the entire 
intron 7 sequenctl remaining in the mature mRNA .. 
The above examples show that the outcomes of splice site mutations 
are varied and result in different mature mRNA transcripts being 
produced. It must also be noted that in these cases a mutation of the 
donor or acceptor splice sites is significant enough to cause structural 
changes in the mature mRNA, which in turn results in phenotypical 
changes in protein synthesis. The nested PCR of patient "G" indicated 
a deletion of under 100 bp, exon 19 is 88 base pairs long, providing a 
candidate area to sequence. This splice site mutation resulted in 
alternate splicing of exon 19, with two mRNA transcripts being 
produced, one with exon 19 the other without. 
The identification of a point mutation in the affected individual by 
sequencing, ailthough accurate, is inefficient when analysing all 
members of the family for the mutation. Demonstration of fragment 
lenglh polymorphism of eDNA, which identified the point mutation 
initially, is an extremely difficult procedure and inefficient when 
analysing all members of the family for the mutation. The requirement 
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of a muscle biopsy makes this method highly invasive and impractical 
when doing chorionic villi sampling or amniocentisis in order to 
provide the family with a pre-natal diagnostic test. Extracting mRNA 
from lymphocytes would make this a much more viable method of 
characterising the mutation in this family (Roberts et al,1990). 
In order for a diagnostic test to be minimally invasive and provide this 
family with an accurate pre-natal diagnosis, the test would have to use 
genomic DNA extracted from whole blood. This diagnostic test would 
also have to distinguish a single base substitution in genomic DNA of 
affected males and carrier females. One method considered was 
Southern blot analysis. If the point mutation introduced or deleted an 
enzyme cutting site, this would lead to a simple and effective Southern 
analysis test. Similarly if the mutation introduced or deleted an enzyme 
cutting site, then exon 19 with part of intron 19 could be amplified 
(PCR) and a restriction digest would identify the affected allele. 
Although the site is palindromic no known restriction enzyme cuts at 
that particular site, so this approach was not an option. 
Another method using restriction enzymes resulted involves the 
introduction of a restriction site by polymerase chain reaction. In this 
method a mis-match is introduced close to the mutation by a mis-
matched primer which anneals to the target DNA. The primer which 
introduces a mutation into the amplified product, is designed to 
introduce a enzyme cutting site, when matched with the mutant allele. 
The normal allele would not have the correct base sequence for the 
enzyme to cut. This test amplifies and gives a signal for both the 
mutant and the affected allele, but only the m'utant allele will be 
digested using the appropriate restriction enzyme. This method has 
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the advantage of providing a signal but of different sizes depending on 
the status of the individual (Schwartz et al, 1991 ). This would be a 
viable method of characterising this point mutation, but due to time 
constraints it was not tested. 
It was decided to use SSCP and the ARMS techniques to characterise 
this "A" to "C" point mutation. Although SSCP analysis is generally 
used in the identification of point mutations, in this case by having a 
point mutation it was possible to optimise the conditions for detecting, 
this point mutation and in the process become familiar with the SSCP 
technique. The SSCP analysis could be then used to find more point 
or minor mutations, in Western Australian dystrophic families (Hayashi, 
1991 ). The ARMS method of characterising this poi~t mutation, 
involved designing primers specific for the mutant and norrna: aJ10Ies 
and then optimising the PCR conditions. These primers, 
normal/affected, would only vary at the end base "A" normal and "C" in 
the affected primer (Billadeau et al, 1991 ). 
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Chapter 5: SINGLE STRANDED CONFORMATION 
POLYMORPHISM 
5.1 Introduction 
This is a method by which the migration of the single stranded DNA 
does not only depend on the number of nucleotides, instead the shape 
of the single stranded DNA determines its rate of migration through a 
non-denaturing polyacrylamide gel. In normal double stranded DNA 
electrophoresis, even on a polyacrylamide gel, it is only possible to 
notice small deletions or insertions of DNA. It is not possible to detect 
substitutions which do not affect the size of DNA and therefore do not 
affect its migration during electrophoresis (Hayashi, 1991 ). Single 
stranded DNA under non-denaturing conditions has a stable shape· 
conformation, which tends to vary depending on the sequence of the 
DNA and the intrastrand reactions. This in turn will cause changes in 
electrophoretic migration depending on the shape of DNA (see Figure 
5.1) (Hayashi, 1991; Baldwin et al, 1992). 
SSCP analysis was carried out on genomic DNA from normal, 
carrier and affected individuals in the affected family. Although this 
method is conventionally used in the detection of point or minor 
mutations, in this case we had already identified a point mutation and 
SSCP analysis was done in order to characterise the mutation and 
provide an easy screening method for the family. As the mutation 
consisted of a single base substitution, fractionation on a 
polyacrylamide gel with its high resolution was determined to be the 
best method (Orita et al, 1989b). Silver staining of agarose gels 
provided a simpler method, but would not have provided the resolution 
of the polyacrylamide gel (Bassam et al, 1991). Orita et al (1989a), 
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Figure 5.1 
SSCP: Migration of double stranded (ds) DNA compared to 
single stranded (ss) DNA during electrophoresis. The ds DNA 
forms a stable conformation, double helix, and migrates 
uniformly dependant on the number of nucleotides. ssDNA 
has different conformational forms dependant on the 
sequence of the strand and the running conditions. The 
complementary strands of DNA when run under appropriate 
SSCP conditions should result in two distinct bands. 
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noted that most point mutations could be detected when analysing 
products less than 500 bases long. As the amplified product was just 
under 500 bases long, approximately 460 bases, it was decided to 
digest the amplified product with restriction enzymes (frequent cutters) 
in order to reduce the fragment size being analysed and therefore 
increasing the chance of detecting a polymorphism . 
5. 2 Materials and Methods 
5 .2.1 Acrylamide stock for SSCP analysis 
Volumes of 1 OOml of 40% Acrylamide gel stock were made up for use 
in SSCP analysis. 1 OOmls of 40% acrylamide contains 39g of 
Acrylamide, 1 g of Bis·Acrylamide and double distilled water to bring 
the volume of the solution to 1 OOml. This mixture was stirred slowly, 
with a magnetic stirrer, until dissolved. 1 Og of mixed bed resin was 
then added to the beaker containing the acrylamide solution and 
stirred slowly for 30 minutes at room temperature. The mixed bed resin 
was then filtered from the acrylamide solution, with funnel and filter 
paper. DOW was then added to the mixed bed resin, located in the 
filter, to bring the volume of acrylamide stock up to 1 OOmls. The 
acrylamide stock solution was stored at 4°C in a bottle wrapped in 
aluminium foil. Since acrylamide is a neurotoxin appropriate safety 
precautions were taken whenever it was handled. This included 
wearing two sets of gloves, a mask and using the fume hood where 
possible. 
5.2.2 6% Acrylamlde gel for SSCP analysis 
SSCP analysis employs a 6% acrylamide solution and SOmis of the 
solution are required to pour Poker Face gel. SOmis of 6% acrylamide 
6S 
solution contains; 12ml of 40% acrylamide stock, Sml of 1 Ox TBE and 
60mls of DOW. Then 170ul of TEMED and 170ul of 25% Ammonium 
persulphate, which had been stored at 4°C, were also added to the 
solution and mixed quickly. The TEMED and 25% Ammonium 
persulphate catalysed the polymerisation of acrylamide, turning the 
acrylamide into a gel within 5 minutes. The acrylamide solution was 
drawn up in a 1 OOml syringe and injected between the two glass 
plates used in the Poker Face system, making sure not to leave air 
bubbles between the plates. A comb, which forms the loading wells, 
was then inserted approximately 5 to 1 Omm into the gel mix. After the 
catalysts had been added, the acrylamide solution was poured quickly 
and the comb inserted between the plates, prior to the gel setting. 
Once the gel had solidified a moist piece of paper was placed over the 
comb and the top end of the gel wrapped in gladwrap to keep in the 
moisture. The gel could then be stored for up to a week at room 
temperature, prior to being used. 
5.2.3 Genomic amplification of exon 19 
Primers used in the amplification of exon 19 from genomic DNA were:· 
(19F)orward 5' TTCTACCACATCCCATTTTCTTCCA 3' 
(19R)everse 5' GATGGCAAAAGTGTTGAGAAAAAGTC 3' 
These primers were specified by Abbs et al (1991). 
Each PCR reaction consisted of 5ul of 5x buffer, 75 ng/ul primer mix, 
0.5 units of Taq Polymerase, 50ng of template genomic DNA, 0.15ul of 
dCTP·32 (50uCi Amersham) and the reaction was brought to volume 
with DOW and overlaid with one drop of paraffin. Thermal cycling of 
samples involved 35 cycles of 94°C for 30 seconds, 55°C tor 1 minute 
and 72°C for 2 minutes (the initial denaturation step at 94°C was 
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carried out tor 5 minutes). An aliquot of 4ul of the samples was taken 
and mixed with 1 ul 5x fico II loading buffer. This was run on a 3% 
agarose gel at 100 volts for 45 minutes. The gel was then stained with 
ethidium bromide and fluoresced under a UV light. This indicated 
whether the samples had amplified. If the amplification worked, then 
the samples were digested with restriction enzymes. 
5.2.4 Digestion of amplified products 
After amplification of the genomic DNA it was digested with three 
known frequent cutters (Hae Ill, Hha I and Hint 1). The only variation in 
digestion conditions for the three enzymes was that Hint I required 
buffer"B", while buffer"C' was used for Hae Ill and Hha I (Promega). 
The digested reactions consisted of 5ul of 1 Ox buffer "C" or "B" 
(depending on the enzyme used), 1 ul of 0.1 M spermidine, 1 ul of 
enzyme (Hae Ill, 11 units/ul or Hha I, 12 units/ul or Hint I, 10 units/ul), 
0.5ul of 1 Omg/ml BSA, 5ul amplified DNA and then brought to volume 
with DOW (Promega). The digest reaction was then incubated for 8 
hours at 37°C, ethanol precipitated, and resuspended in 1 Oul of DOW 
and 1 Oul of formam ide loading buffer. 
5.2.5 Ethanol precipitation 
To the DNA sample was added, 3M NaAc (1/10th the volume of the 
DNA sample) and then 100% cold ethanol (3 times the volume of the 
DNA sample). The sample was then vortexed lightly and left at -80°C 
for 2 hours to precipitate. After the DNA had precipitated, the sample 
was then spun down at 13650g for 15 minutes and the supernatant 
poured off. The DNA pellet was then washed by adding 70% cold 
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ethanol (3 times the total volume of original DNA sample) and then the 
pellet was spun down for 5 minutes at 15000rpm. The 70% ethanol 
was then poured off the DNA pellet, which was then vacuum dried and 
resuspend in DOW. 
5.2.6 Running 6% polyacrylamide gel for SSCP analysis 
5ul of the digested DNA was aliquoted into a fresh tube to be run 
under non-denaturing conditions. The rest of the digested DNA was 
run under denaturing conditions for SSCP analysis. This involved 
heating the sample to 80°C which denatured the DNA. After 10 
minutes 2ul of the hot, denatured DNA was loaded onto a 6% non 
denaturing polyacrylamide gel (Poker Face) and run in 1 x TBE butter. 
2ul of the non-denatured DNA was also run on the same gel. The gel 
was then run for 8 hours at 400 volts. Prior to loading the samples, the 
polyacrylamide gel was pre-run for 30 minutes at 400 volts. The final 
step involved fixing, drying and exposing the polyacrylamide gel as 
described in 3.6.2. 
5.3 Results 
Single strand conformation polymorphism analysis of exon 19 using 
genomic DNA amplified with primers 19F and 19R, indicated a 
polymorphism, therefore providing a means of characterising the point 
mutation found in this BMD family. In Figure 5.2 the uncut DNA showed 
no polymorphism in samples 1 to 4 both in the normally 
electrophoresed and those samples in which SSCP analysis was 
performed. It is important to note that single stranded DNA (ssDNA) 
migrates much slower than double stranded DNA (dsDNA), during 
electrophoresis. Therefore for all digests in Figure 5.2 sample 1 has 
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Figure 5.2 
SSCP analysis: Autorad showing amplified exon 19 samples 
for "1" normal female, 112" carrier female, "3" BMD male, "4" 
normal male. These samples were run uncut and also cut with 
the restriction enzymes Hae Ill, Hha I, Hinf I. pUC 19 marker 
digested with Msp I. Sample 1 was loaded twice for each 
digest first as double stranded DNA and then as single 
stranded DNA. 
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been loaded twice. The first time as dsDNA and the second time under 
SSCP conditions. This gives an indication of how the double stranded 
DNA has migrated in relation to the single stranded (SSCP) DNA. 
The Hae Ill digested DNA showed no polymorphism with SSCP 
analysis (see Figure 5.2). The DNA digested with Hha I showed a 
polymorphism with SSCP analysis; samples 2 and 3 have only two 
bands corresponding to carrier female and affected male, samples 1 
and 4 have three bands corresponding to normal female and normal 
male (see Figure 5.2). In Figure 5.2 Hha I has either cut the amplified 
exon 19 at the very end of the amplified product ie. in the primer 
sequence or the enzyme has not cut at all. As there is no Hha I 
restriction site in the primers (t 9F and 19R), this indicates that Hha I 
has not cut exon 19, as any cutting of exon 19 inside the primers would 
result in a different sized product compared to the uncut samples (see 
Figure 5.2). The only variation between the uncut SSCP and the Hha I 
samples was that the Hha I samples were ethanol precipitated where 
as the uncut samples were loaded straight from the amplification 
reaction. The uncut SSCP samples have salts and MgCI2 from the 
amplification buffer, these would not be present in the Hha I SSCP 
samples, this could account for the variation with the Hha I SSCP 
samples as seen in Figure 5.2. The Hint I digest of the four 
amplification products resulted in at least two products. The smaller 
SSCP product can just be seen on Figure 5.2 at the bottom of the 
autorad. The second larger product shows a polymorphism using 
SSCP analysis. Samples 2 and 3 show two distinct bands indicating 
carrier female "2" and affected male "3" while normal female "1" and 
normal male "4" have only one band (see Figure 5.2). 
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5.4 Discussion 
Orita et al (1989b), indicated that a number of factors can influence the 
migration of single stranded DNA. For example, the sequence and the 
size of the DNA fragments (determined by restriction enzyme), the 
temperature, the pH and gel concentration are all important in 
determining rate of migration through a non-denaturing 
polyacrylamide gel. By varying the conditions of SSCP analysis it is 
possible detect most base changes in DNA under 200bp. Optimisation 
of the DNA samples 1 to 4 in order to show a polymorphism included 
varying the current, the temperature and the running time of gels (data 
not shown). Once conditions had been optimised it was possible to 
detect a single base change in an amplified product which was just 
over 460 bases (see Figure 5.2). This could be due to a single strand 
of DNA having more than one stable conformation under a given set of 
conditions. This would result in 2 bands from single stranded DNA with 
the same sequence as described by Orita et al, (1989b). 
Once the conditions for SSCP analysis were optimised it was possible 
to determine which individuals had the single base substitution. One 
problem was that there was no distinction between carrier female and 
affected male, therefore a sex determination test must also be done in 
order to provide the family with adequate information to make an 
informed decision based on the prenatal tests. This may be a 
characteristic of this specific test as Orita et al (1989a), demonstrated 
different conditions change the characteristics of migration. It may 
therefore be possible to improve on this test, by changing the running 
conditions, resulting in a test which is able to distinguish between 
affected males and carrier females. 
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This test provided a relatively simple method of analysing members of 
the family for the point mutation, although time consuming and 
requiring the use of 32P, it must be considered an option for prenatal 
diagnostic testing. 
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Chapter 6: AMPLIFICATION REFRACTORY 
MUTATION SYSTEM 
6.1 Introduction 
Amplification refractory mutation system (ARMS). or allele specific 
amplification. is a method which makes it possible to amplify DNA 
specific to the mutation or specific for the normal allele. This method 
uses genomic DNA in polymerase chain reaction (PCR). 
Normal and mutant alleles are identified by using two allele specific 
oligonucleotide primers. The normal and the affected primer mixes 
have a common reverse primer while the forward primer varies 
between the normal ("T" at the 3' end) and affected primer mixes ("G" at 
the 3' end). Fragment amplification occurs only when the allele specific 
. primer matches the nucleotide sequence of the template DNA. The 
amplified product is detected by agarose gel electrophoresis. followed 
by staining with ethidium bromide (Wenham et at 1991; Billadeau et at 
1991 ). This method of characterising the point mutation requires 
sequence information which was derived from the sequencing of exon 
. 
19, in, order to design forward primers (l9FA and 19FC) which are 
complementary to the 5' end of intra~ ·19. The primers for the normal 
and affected allele vary only at the 3' end base, which··~aries from an 
"T" for the normal primer to a "G" for the affected primer (see Figure 
6.1 ). Once the normal and affected primer mixes were optimised, they 
would only anneal and allow amplification when their respective 
alleles were present in genomic DNA. Therefore a carrier female 
would have the normal and affected primer mixes giving a signal . 
. 
Affected males would only get a signal from the affected primer mix, 
while normal males and females would only get a signal from the 
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Figure 6.1 
ARMS analysis: a) The BMD primers shown here will only 
amplify up the genomic DNA if the mutation which causes 
' 
, .BMD in this family is present b) The normal primers will only 
amplify, genomic DNA, when the normal allele is present 
Reactions (a & b) are specific for their respective alleles and 
,only result in amplification when that particular allele is 
present 
• 
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normal primer mix. The size of the signal for the normal and affected 
primer mixes does not vary as the primers amplify the same region of 
DNA but are specific for the 3' base change. One of the problems that 
could be encountered with this method of characterisation is that of 
getting false negatives. How do you know if the negative result is due 
to the primer not annealing to the DNA or whether the whole reaction 
ha$ not worked? Wenham et al, (1991) suggested having a second set 
of primers in the reaction (internal control) with a different sized 
product. In this way it is possible to tell if the reaction has worked, 
reducing the chance of false negatives. The ARMS method of 
characterising a single base mutation was described by Wenham et al 
(1991) as "simple, reliable and robust and avoiding the use of radiation 
or hybridisation with allele specific oligonucle<;>tide probes". This 
makes for an ideal diagnostic test! 
No single protocol is appropriate for all situations, it is therefore 
necessary to optimise each reaction in order to maximise the yield of 
the desired product, as opposed to non-specific background bands, 
primer dimers and mutations or heterogenicity (Innis et al, 1990). 
The magnesium concentration can affect a· number of factors within a 
PCR' reaction including primer annealin'g, product specificity, formation 
of pri,;;er dimers and enzymatic activity. Taq polymerase requires free 
magnesium on top of that bound by template DNA;· primers and 
dNTP's. Therefore PCR reactions should contaln between 0.5 and 
2.5 mM MgCI2. Decreasing the magnesium concentration leads to an 
increase in specificity (Innes et al, 1990). 
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The temperature and length of time required for primer annealing 
depends upon the base composition as well as the length and 
concentration of the amplification primers. Annealing temperatures 
between 55°C and 72°C generally yield the best results, with 
increased annealing temperature leading to greater specificity of 
amplification (Innis et al, 1990). 
The number of cycles depends on the concentration of target DNA. Too 
many cycles can lead to non-specific bacl<nround products, while too 
few cycles will give a low product yield. As a rule, however, to go over 
40 cycles without getting a signal from a reaction indicates that 
something is wrong (Innis et al, 1990). 
Primer concentrations 0.1 to 0.5uM provide optimal conditions for PCR 
reactions. Primer concentrations above 0.5uM can lead to non-specific 
products being produced and also primer dimers annealing to each 
other. Primer concentrations below 0.1 uM may lead to insufficiGnt 
amplified product being produced (Innis et al, 1990) . 
Efficient primers should be 18 to 28 nucleotides long with a 50 to 60% 
"G" and "C" composition. The 3' end of primer pairs should not be 
complementary, this helps to reduce 'the formation of primer dimer 
• • 
artifacts. It is also important to avoid long stretches of "C'~ and "G" at the 
3' end of primers as this may promote mispriming at "G" and "C" rich 
sequences and palindromic sequences within primers (a sequence 
that reads the same in both directions). In some cases a primer may 
not work, due to the secondary structures within the template DNA. In,. 
such cases it may be necessary to design another set of primers for 
that region (Innis et al, 1990). 
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6.2 Materials and Methods 
Primers specific to the mutation in axon t 9 and primers for the normal 
allele were produced from the sequence data, obtained in chapter 4 
(see Table 6.1 ). It was then necessary to optimise the conditions for 
each set of primers. 
6.2.1 Optimised normal primer 
PCR reaction consisted of Sui of Sx buffer (no MgCI2 in this buffer), 2ul 
of primer mix 80ng/ul, O.S units of Taq Polymeras·e, 1.7mM of MgC12, 
SOng of genomic DNA and then brought to the volume with DOW and 
, overlaid with one drop of paraffin. Thermal cycling of samples 
involved 33 cycles of 94°C for 3 seconds, 56°C for 1 minute and 72°C 
for 2 minutes (the initial denaturation step at 94°C was carried out for S 
minutes). 
6.2.2 Optimised affected primer 
PCR reaction was carried out as per normal primer, except the normal 
Sx butter was used giving the reaction a MgCI2 concentration of 2mM 
and the annealing temperature was change,d ·from S6°C to S8°C . 
. 
6.2.3. Running ARMS products ' 
,. 
• 
The products produced by the ARMS amplification were run on a 3% 
,. 
agarose gel at 7S volts for 90 minutes, the gel was then stained with 
ethidium bromide and observed under UV light. The product size will 
not vary from "normal" to the "affected" allele. Instead, a signal will only 
occ~r when the affected and normal primers anneal to their exact 
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Table 6.1 
Primers used in ARMS analysis 
Sequence (5' to 3') 
PRIMERS USED TO AMPLIFY NORMAL ALLELE 
PRIMER"A" 
19R GATGGCAAAAGTGTTGAGAAAAAGTC 
19FA TATCTAAATCAACTCGTGTAATT 
PRIMERS USED TO AMPLIFY AFFECTED ALLELE 
PRIMER"C" 
19R GATGGCAAAAGTGTTGAGAAAAAGTC 
19FC TATCTAAATCAACTCGTGTAATG 
Prim~r 19R was specified by Abbs et a1,(1991). 
,. 
• 
.. 
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complementary sequence on the template DNA. This means that the 
identification of the disease and normal allele is done simply by the 
presence or absence of a signal, when doing an amplification, 
dependent on which set of primers is being used. 
6.3 Results 
Optimisation of the ARMS primer was achieved by varying a number of 
the PCR conditions. This included varying the number of cycles, the 
annealing temperature (data not shown) and. the MgCI2 concentration 
(see Figure 6.2). In Figure 6.2 the annealing temperature and the 
, number of cycles (PCR) remained constant for both the "normal A" 
primer and the "affected C" primer mixes, only the MgCI2 concentration 
was varie~ Figure 6.2 shows that the "affected C" primer worked well 
at both 2mM MgCI2 and 1 mM MgCI2 ie. only the BMD male and carrier 
female have the affected allele, as expected. The "normal A" primer in 
figure 6.2 indicated at a 2mM MgCI2 concentration that the BMD male 
had a normal allele when using "normal A" primer. The BMD male 
should not have the normal allele. Reducing the MgCI2 concentration 
to 1 mM MgCI2 when using the "normal A" primer resulted in no signal 
in anY, of the four samples (see Figure ,6.2). The expected result using 
"normal A" primer is that only Normal Male/Female and, Carrier Female 
would have this allele. In order to optimise the "normal A" primer the 
" 
MgCI2 was then varied between 1 and 2mM, along with the PCR 
conditions, until the expected result was obtained as in Figure 6.4. 
Polymerase chain reaction provides a very effective way of analysing a 
sequence of DNA. The amplification of a sequence of DNA many 
. 
millions of times can lead to contamination of subsequent PCR 
reactions therefore making it necessary to have a negative control in 
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Figure 6.2 
Optimising ARMS reaction: Varying the MgCI2 concentration 
' 
from 1 to 2mM, while maintaining all other PCR conditions. 
Primer "A" should only amplify the normal allele, while primer 
"C" should only amplify the affected allele. Lambda marker 
' 
· digested with Pst I. 
,. 
• 
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all PCR reactions and special lab procedures to minimise 
contamination. In Figure 6.3, while attempting to optimise the 
conditions tor both the "affected C" primer and the "normal A" primer, 
the reaction was contaminated resulting in a signal in the "normal A" 
primer negative control. It was then necessary to do this amplification 
again, making sure not to contaminate the reaction (data not shown). 
Once both "normal A" and "affected C" primers were optimised (see 
Figure 6.4) it was possible to distinguish a BMD male who only had the 
affected allele and a carrier female who had both the affected allele 
and the normal allele. Normal males/females only had the normal 
allele. 
Once the conditions had been optimised, all the family members of 
patient "G", for which genomic DNA was available were tested in a 
. double blind test. This test involved getting genomic DNA from as 
many members of patient "G"s family as possible. These samples were 
only numbered and by using the ARMS test it was possible .to 
determine whether the samples came from normal individuals, carrier 
females or affected males (data noy shown). 
6.4 '· Discussion 
The A'RMS method of characterising this "A" to "C" poinfmutation in the 
family of patient "G" proved to be very simple and effective once the 
conditions had been optimised. The nature of PCR reactions make 
them susceptible to contamination. It is therefore important to both 
follow protocols which minimise the likelihood of contamination (Erlich, 
1989) and also to always have a negative control. The double 
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Figure, 6.3 
Contamination of ARMS reaction: The ·ve control Primer "A" 
has given a signal. pUC marker digested with Msp I. 
.-
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Figure, 6.4 
ARMS roqction optimised for BMD family: Primer "A" amplifies 
only when normal allele is present, while primer "C" only 
amplifies when the affected allele is present. pUC. marker 
digested with Msp I. 
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blind ARMS test that was carried out supp01ied previous linkage 
analysis done on all family members at this laboratory. These allele 
specific oligonucleotide tests therefore provided an extremely easy 
and specific meth0d for detecting this mutation. 
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Chapter 7: GENERAL DISCUSSION 
Point or minor mutations in the dystrophin gene account for 30% of 
DMD and BMD patients (Laing, 1993) In Western Australia this 
amounts to twenty families. These families are offered prenatal 
diagnostic testing based on linkage analysis. In linkage analysis the 
probability of the disease causing allele travelling with a polymorphic 
marker is determined. The closer the marker to the mutation, the more 
likely it is to travel with the mutation. It is then possible with an 
informative marker and an extended family, to determine the 
probability of the marker travelling with the mutant allele. Linkage 
analysis provides a probability based test which results in a LOD 
score, where the LOD score is the logarithm to the base 10 of the odds 
of linkage between a marker and the disease gene (Gelehrter and 
Collins, 1990, p. 206). A LOD score of +3 means odds of 1000:1 in 
favour of linkage, whereas a LOD score of -2 means odds of 100:1 
against linkage. In practice LOD scores are calculated for different 
distances/number of nucleotides (9) between the marker and the 
disease gene, from 0 to 50 centiMorgans. At 50 centiMorgans genes 
are considered unlinked. 
likelihood (data\8) 
Likelihood ratio (9) = 
likelihood (data\no linkage) 
(Gelehrter and Collins, 1990, p. 205) 
The higher/more positive the LOD score the more likely the marker and 
the disease gene are linked. Of course if a high LOD score occurs at a 
low (9) value the genes are closely linked (Gelehrter and Collins, 
1990, p. 206). It has been estimated that in 33% of dystrophic patients, 
the mutation first occurs in the affected male. In another 33% of 
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dystrophic males the mutation first occurred in their mother and in the 
final 33% of dystrophic males the mutation first occurred with their 
grandmother (Laing, 1993). Linkage analysis therefore can not always 
determine the status of the family members who have a relative 
suffering . DMD or BMD as the mutation may be de-novo or the 
pedigree not large enough to provide accurate linkage analysis for that 
family (Laing, 1993). It is important in these families to locate the actual 
mutation to provide them with an accurate prenatal diagnostic test. 
This test could also eventually result in the eradication of the mutant 
allele in future generations, in these families. 
The procedure for locating and characterising point mutations takes 
advantage of a number of molecular techniques. PCR provides the 
basis for detection .and analysis of these point mutations. This 
technique, although very powerful, is subject to contamination by 
previously amplified products (see Figure 6.3). It is very important to 
use procedures that limit cross contamination of PCR products and the 
most effective way of accomplishing this is to use a PCR dedicated 
micropipette to load all amplified products. The use of sterile technique 
and a PCR dedicated micropipette resulted in only one instance of 
contamination. 
A point mutation was identified in patient 'G'. This mutation was in the 
consensus sequence at the 5' end of intron 19. The base after the 
universally conserved donor splice site had changed from "A" to "C". 
This point mutation was subsequently characterised by SSCP and 
ARMS analysis, providing this family with accurate diagnostic tests. 
Patient 'G' has a splice site mutation which results in exon 19 being 
spliced out. This is a frameshift mutation and would generally indicate 
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DMD phenotype (Monaco et at, 1988). However patient 'G' has BMD 
which could be explained by alternate splicing resulting in some lui\ 
length mRNA transcript which maintains the reading frame. This 
alternate splicing is demonstrated by the two PCR products for patient 
'G', exons 17·25 in figure 3.4, ana the normal size and the other 
smal\er as a result of exon 19 being deleted. Chelly et at (1990) 
describes two cases in which BMD patients, had apparent out ol frame 
gene deletions, which according to the frameshift hypothesis of 
Monaco eta\ (1988), should result in DMD. It was noted, though, that in 
these patients alternate splicing had occurred and this restored the 
reading frame. Roberts et at (1991) also describes a patients with a 
frameshift mutation caused by a deletion of exons 42 and 43 of the 
dystrophin gene. Subsequent analysis showed alternate splicing 
which resulted in two mRNA transcripts. The minor product results in 
exon 44 also being excluded which resulted in the restoration of the 
reading frame. This could explain the mild phenotype that was 
observed in this patient. 
The point mutation found in patient 'G' and the subsequent 
characterisation of this point mutation by sequencing, SSCP and al\ele 
specific amplification will provide this family with a diagnostic test. 
Each of these methods have their own limitations. For example 
sequencing gels can be hard to read (cross·banding) and SSCP and 
al\ele specific amplifications can be hard to optimise. A diagnostic test 
would be of considerable importance should a carrier ~emale ever 
decide to have a child. The allele specific amplification test devised for 
this family was the easiest test to perform and interpret, once the 
conditions had been optimised. Yet SSCP analysis may be used as a 
confirmatory test in prenatal diagnosis. Prenatal diagnostic tests on 
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family members of patient 'G' previously performed by this laboratory 
consisted of linkage analysis. The limitations of this procedure have 
already been noted. The allele specific amplification test detects the 
actual point mutation reducing the chance of mis-diagnosis. 
The identification and characterisation of this one point mutation in 
patient 'G' is of no direct consequence to the other families throughout 
Western Australia who also have a small disease causing mutation in 
the dystrophin gene. The successful identification of this point mutation 
could hold some hope for them that, in the not to distant future, a 
similar feat may .be achieved for them. However, in the meantime these 
families still rely on linkage analysis for prenatal diagnosis, which in 
many cases is uninformative and until such time that their specific 
mutations are characterised, the accuracy of their diagnoses can not 
be assured. 
The mutation in patient 'G' resulted in a complete exon being skipped 
most of the time. This mutation only becomes obvious when mRNA 
was converted to eDNA and then the eDNA amplified. The major 
problem with this technique was the mRNA for dystrophin is mainly 
present in muscle, a tissue that was/is often hard to obtain from 
patients with BMD or DMD (Chelly et al, 1991 ). When it is obtained it is 
often fibrous and the muscle cells have degenerated (Kaido et al, 
1991 ). Chelly et al (1991) noted that illegitimate transcription occurs in 
all cell types and that the illegitimate transcripts are a bona fide version 
of tissue specific mRNA. Chelly et al (1991) also showed it was 
possible to extract from non-specific cell types (lymphocytes), 
illegitimate mRNA which is tissue specific for, say, muscle cells. 
Although the presence of this illegitimate transcript can be up to 25 
000 times less in such non-specific cells (Chelly et al 1988), this 
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method of mRNA extraction from non-specific cells, should provide a 
much more practical and less traumatic means of obtaining mRNA 
from dystrophic patients in the future. 
SSCP provides a means of characterising a mutation (which was done 
with patient 'G') as well as a means of locating point mutations (Orita et 
al, 1989b). Another method, mis-match analysis, encourages 
heteroduplexes to be formed between normal and affected DNA. The 
resultant mis-matches are incubated with osmium tetroxide and then 
incubated with piperidine to cleave the DNA at the mis-match. End 
labelling of one primer wiil indicate where the mutation lies. (Cotton et 
al, 1988; Roberts et a\, 1989). This may provide a much more effective 
way of looking at the amplified eDNA transcript of the dystrophic 
' patients with point mutations. Roberts et al (1989), indicates that all 
types of mutations may be identified using the mis-match cleavage 
method. However the mis-match cleavage method does use highly 
toxic chemicals and this is a major disadvantage of the technique. 
Future research in identifying point mutations in the dystrophin gene 
and any other localised gene would need to consider the techniques 
of extracting mRNA from non-specific cells and the mis-match 
cleavage technique. It is hoped that by using these new techniques, 
the trauma to the patient will be reduced as will the time needed to 
characterise each point or minor mutation. These procedures of 
locating and then working up a diagnostic test specific for the mutation, 
will become common laboratory practices in the future. A!\hough time 
consuming at present, locating these point mutations provides thes•3 
families with the confidence to make an informed decision about 
whether or not to have more children. 
97 
TABLE A) BUFFERS AND ETHIDIUM BROMIDE 
ELECTROPHORESIS BUFFERS 
BUFFER 
Tris~acetate 
(TAE) 
Trls-borate 
(TBE) 
WORKING 
SOLUTION 
1x: 0.04M Trls-acetate 
0.001M EDTA 
0.5x: 0.045M Tris-borate 
0.001M EDTA 
GEL LOADIWl BUFFERS 
BUFFER TYPE BUFFER 
Ficoll 0.25% bromophenol blue 
(6x) 0.25% xylene cyanol FF 
CONCENTRATED STOCK 
SOLUTION (per Litre) 
sox: 242g "fris base 
57.1 ml glacial acetic acid 
100rr.l 0.5M EDTA (pH 8.0) 
5x: 54g Tris base 
27 .Sg boric acid 
20ml 0.5M EDTA (pH 8.0) 
STORAGE 
TEMPERATURE 
room temp 
15% Ficoll (Type 400; Pharmacia) 
in water 
Formamlde 98% deionized formamide 
(1X) 10mM EDTA (pH 8.0) 
0.025% xylene cyanol FF 
0.025% bromophenol blue 
ETHIDIUM BROMIDE 
STOCK CONCENTRATION 
10mg/ml 
(1g of Elhidium Bromide 
in 100ml of H20) 
(Sambrook et al, 1989) 
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STAINING CONCENTRATION 
O.Sug/ml 
' 
TABLE B) ABBREVIATIONS 
AMV·RTase Avian myeloblastosis virus reverse 
transcriptase 
ARMS Amplification refractory mutation system 
APS Ammonium persulphate 
BMD Backer muscular dystrophy 
bp Base pairs 
eDNA Complementary deoxyribonucleic acid 
ddATP Dideoxyadenine triphosphate 
ddCTP Dideoxycytosine triphosphate 
ddGTP Dideoxyguanine triphosphate 
ddNTP Dideoxynucleotide triphosphate 
, , ddTTP Dideoxythymine triphosphate 
DOW Double distilled water 
DMD Duchenne muscular dystrophy 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotlde triphosphate 
dsDNA Double stranded deoxyribonu9leic acid 
kb Kilobases 
mRNA Messenger ribonucleic acid 
PCR Polymerase chain reaction 
rRNA Ribosomal ribonucleic acid 
RNA Ribonucleic acid 
snRNA Small nuclear ribonucleic aGid 
SSCP Single strand conformation polymorphism 
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ssDNA Single stranded deoxyribonucleic acid 
T AE Tris-acetate 
TBE Tris-borate 
TEMED N,N,N',N',-Tetramethyl~thylenediamine 
I 
!RNA Transfer ribonucleic acid 
UV Ultra-violet 
V Volts 
SDS Sodium dodecyl sulfate 
EDTA Disodium ethylenediaminetetraacetate 
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